| Sector |
Healthcare
|
Compare with Sector peers |
| Industry |
Pharmaceuticals & Drugs
|
Compare with Industry peers |
| Website | http://www.lykalabs.com | |
| Market Cap | 399.23 Cr. | |
| Enterprise Value(EV) | 450.79 Cr. | 2023-09 |
| Financial Indicators | ||
|---|---|---|
| Earnings per share (EPS) | -1.08 | Trailing Twelve Months Ending 2023-12 |
| Price-Earning Ratio (PE) | - | Trailing Twelve Months Ending 2023-12 |
| Industry PE | 41.93 | Trailing Twelve Months Ending 2023-12 |
| Book Value / Share | 21.22 | Trailing Twelve Months Ending 2023-12 |
| Price to Book Value | 5.68 | Calculated using Price: 120.65 |
| Dividend Yield | 0.00 | Period Ending 2023-03 |
| No. of Shares Subscribed | 3.31 Cr. | 33,090,000 Shares |
| FaceValue | 10 | |
| About Lyka Labs Ltd. | ||
| Lyka Labs Ltd was incorporated on December 29, 1976 as a private limited company and converted into a public limited company on December 19, 1985. | ||
| 1 Day |
|
-3.29% |
| 1 Week |
|
-5.60% |
| 1 Month |
|
+13.73% |
| 3 Month |
|
+0.71% |
| 6 Month |
|
+8.95% |
| 1 Year |
|
+17.22% |
| 2 Year |
|
-23.95% |
| 5 Year |
|
+314.80% |
| 10 Year |
|
+870.99% |
| 9 years | 2015-06 | 2016-03 | 2017-03 | 2018-03 | 2019-03 | 2020-03 | 2021-03 | 2022-03 | 2023-03 | |
| Return on Equity (%) | -13.05 | 11.74 | -18.27 | -46.3 | -14.2 | -448.65 | 0 | 0 | -63.63 | |
| Return on Capital Employed (%) | 11.73 | 12.41 | 6.66 | -6.52 | -5.5 | -31.39 | 8.95 | 56.68 | -1 | |
| Return on Assets (%) | -1.55 | 1.58 | -2.7 | -8.02 | -2.97 | -32.05 | -5.58 | 21.4 | -7.8 |
| Particulars | 10 years | 2015-06 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-09* Rs. Cr. |
| Shh. Funds | 43 | 45 | 38 | 49 | 43 | -14 | -26 | 13 | 45 | 68 | |
| Non Curr. Liab. | 37 | 29 | 39 | 5 | 72 | 137 | 149 | 73 | 73 | 53 | |
| Curr. Liab. | 195 | 163 | 165 | 167 | 85 | 66 | 50 | 99 | 33 | 30 | |
| Minority Int. | 4 | 4 | 7 | 3 | 3 | -1 | 1 | 0 | 0 | 0 | |
| Equity & Liab. | 279 | 241 | 249 | 225 | 203 | 188 | 174 | 186 | 152 | 152 | |
| Non Curr. Assets | 177 | 159 | 186 | 176 | 168 | 152 | 145 | 133 | 107 | 105 | |
| Curr. Assets | 102 | 82 | 63 | 49 | 35 | 36 | 29 | 52 | 44 | 47 | |
| Misc. Exp. not W/O | |||||||||||
| Total Assets | 279 | 241 | 249 | 225 | 203 | 188 | 174 | 186 | 152 | 152 |
| Particulars | 10 years | 2015-06 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. | 2023-12 Rs. Cr. TTM |
| Net Sales | 166 | 130 | 110 | 60 | 71 | 61 | 86 | 194 | 93 | 106 | |
| Other Income | 2 | 2 | 2 | 2 | 2 | 3 | 2 | 2 | 3 | 2 | |
| Total Income | 169 | 132 | 112 | 62 | 73 | 65 | 88 | 196 | 96 | 107 | |
| Total Expenditure | -138 | -110 | -87 | -63 | -73 | -65 | -67 | -93 | -76 | -89 | |
| PBIDT | 31 | 22 | 25 | -1 | 0 | -1 | 21 | 103 | 20 | 19 | |
| Interest | -26 | -16 | -19 | -10 | -7 | -20 | -26 | -20 | -12 | -7 | |
| Depreciation | -11 | -9 | -10 | -11 | -7 | -8 | -8 | -17 | -14 | -13 | |
| Taxation | -1 | 0 | 2 | 1 | 9 | -1 | 4 | -21 | 0 | -1 | |
| Exceptional Items | 2 | 7 | -4 | 2 | -1 | -33 | -1 | -7 | -7 | -1 | |
| PAT | -5 | 4 | -7 | -19 | -6 | -63 | -10 | 38 | -13 | -4 | |
| Minority Interest | 0 | 0 | 1 | 2 | 1 | 2 | -1 | 1 | 0 | 0 | |
| Share Associate | |||||||||||
| Other Related Items | |||||||||||
| Consolidated Net Profit | -5 | 4 | -6 | -17 | -6 | -61 | -12 | 39 | -13 | -4 | |
| Adjusted EPS | -2 | 2 | -3 | -6 | -2 | -21 | -4 | 14 | -4 | -1 |
| Particulars | 10 years | 2014-06 Rs. Cr. | 2015-06 Rs. Cr. | 2016-03 Rs. Cr. | 2017-03 Rs. Cr. | 2018-03 Rs. Cr. | 2019-03 Rs. Cr. | 2020-03 Rs. Cr. | 2021-03 Rs. Cr. | 2022-03 Rs. Cr. | 2023-03 Rs. Cr. |
| Cash Fr. Operatn. | 89 | 27 | 12 | 31 | 11 | 27 | 5 | 9 | 79 | 9 | |
| Cash Fr. Inv. | -57 | 29 | 17 | -13 | -3 | -4 | 0 | 0 | -6 | 7 | |
| Cash Fr. Finan. | -26 | -60 | -30 | -19 | -10 | -23 | 3 | -12 | -63 | -22 | |
| Net Change | 6 | -4 | -1 | 0 | -3 | -1 | 9 | -3 | 10 | -5 | |
| Cash & Cash Eqvt | 11 | 7 | 6 | 5 | 2 | 2 | 10 | 7 | 17 | 12 |
|
Fri, 26 Apr 2024
Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A Format of Initial Disclosure to be made by an entity identified as a Large Corporate.
We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26 2018. No Name of the Company Secretary: Kishore P Shah Designation: Company Secretary and Compliance Officer EmailId: companysecretary@lykalabs.com Name of the Chief Financial Officer: Yogesh Shah Designation: Executive Director and CFO EmailId: ybshah@lykalabs.com Date: 26/04/2024 Note: In terms para of 3.2(ii) of the circular beginning F.Y 2022 in the event of shortfall in the mandatory borrowing through debt securities a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore an entity identified as LC shall provide in its initial disclosure for a financial year the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. |
|||||||||||||||||||||
|
Thu, 18 Apr 2024
Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations 2011 for Ipca Laboratories Ltd & PACs |
|||||||||||||||||||||
|
Thu, 18 Apr 2024
Certificate Under Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulation 2015 Certificate under Regulation 7 (3) of the SEBI ( Listing Regulations and Disclosure Requirements) Regulation 2015 is enclosed. |
| Tue, 30 Apr 2024 |
Opening at High
|
Closing Below Previous Low
|
Making Lower Lows for 3 days
|
Making Lower Lows for 2 Days
|
High Increase in 1 Month
|
